Jeroen J.W.M. Janssen

Bone marrow stromal proteoglycans regulate megakaryocytic differentiation of human progenitor cells.

Reduced supportive capacity of bone marrow stroma upon chemotherapy is mediated via changes in glycosaminoglycan profile.

Towards cure of CML: why we need to know more about CML stem cells?

A 51-year-old male CML patient with progressive hearing loss, confusion, ataxia, and aphasia during imatinib treatment.

Economic evaluation of posaconazole versus fluconazole prophylaxis in patients with graft-versus-host disease (GVHD) in the Netherlands.

Methylation patterns in CD34 positive chronic myeloid leukemia blast crisis cells.

Chronic myeloid leukemia lysate-loaded dendritic cells induce T-cell responses towards leukemia progenitor cells.

Clinical validation of dried blood spot sampling in therapeutic drug monitoring of ciclosporin A in allogeneic stem cell transplant recipients: direct comparison between capillary and venous sampling.

High-dose imatinib versus high-dose imatinib in combination with intermediate-dose cytarabine in patients with first chronic phase myeloid leukemia: a randomized phase III trial of the Dutch-Belgian HOVON study group.

Imatinib discontinuation in chronic phase myeloid leukaemia patients in sustained complete molecular response: a randomised trial of the Dutch-Belgian Cooperative Trial for Haemato-Oncology (HOVON).

Study protocol of the RAND-study: a multicenter, prospective cohort study investigating response and adherence to nilotinib treatment in chronic myeloid leukemia.

Risk factors for relapse after allogeneic transplantation in acute myeloid leukemia.

Nilotinib first-line therapy in patients with Philadelphia chromosome-negative/BCR-ABL-positive chronic myeloid leukemia in chronic phase: ENEST1st sub-analysis.

Dried blood spot sampling of nilotinib in patients with chronic myeloid leukaemia: a comparison with venous blood sampling.

Influence of WHO versus ELN advanced phase chronic myeloid leukemia definitions on overall survival.

Treatment outcome in a population-based, 'real-world' cohort of patients with chronic myeloid leukemia.

Impact of hospital experience on the quality of tyrosine kinase inhibitor response monitoring and consequence for chronic myeloid leukemia patient survival.

Prevalence and associated factors of medication non-adherence in hematological-oncological patients in their home situation.

Patient satisfaction with information on oral anticancer agent use.

Ponatinib in chronic myeloid leukemia (CML): Consensus on patient treatment and management from a European expert panel.

Omitting cytogenetic assessment from routine treatment response monitoring in chronic myeloid leukemia is safe.